Company Profile

Elanix is a Swiss Life Science company dedicated to regenerative medicine using progenitor cells stored and expanded in its own GMP validated Master Cell Bank. Elanix is the sole owner of a set of skin progenitor cell lines that can be further multiplied generating over 35 billion of 10×10 cm advanced wound dressings without any further cell technology related costs. Elanix has the option to license to two patents invented by the founder during the tenure as a professor in the University Hospital of Lausanne, Switzerland (CHUV).